High Platelet Count is a Potential Prognostic Factor of the Early Recurrence of Hepatocellular Carcinoma in the Presence of Circulating Tumor Cells

References

• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–955. doi:10.1097/sla.0000000000000710
   PubMed Web of Science ®Google Scholar
• Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436. doi:10.1002/hep.31165
   PubMed Web of Science ®Google Scholar
• Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78(16):4731–4744. doi:10.1158/0008-5472.Can-17-2459
   PubMed Web of Science ®Google Scholar
• Yu XQ, Dasgupta P, Baade P. Quantifying the absolute number of cancer deaths that would be avoided if cancers were diagnosed prior to progressing to distant metastasis, New South Wales, Australia 1985–2014. Int J Cancer. 2022;150(11):1760–1769. doi:10.1002/ijc.33931
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904. doi:10.1038/nm1469
   PubMed Web of Science ®Google Scholar
• Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–1122. doi:10.1016/j.cell.2014.07.013
   PubMed Web of Science ®Google Scholar
• Wei C, Yang C, Wang S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64. doi:10.1186/s12943-019-0976-4
   PubMed Web of Science ®Google Scholar
• Wang PX, Xu Y, Sun YF, et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2021;41(3):562–573. doi:10.1111/liv.14734
   PubMed Web of Science ®Google Scholar
• Mocan T, Simão AL, Castro RE, et al. Liquid biopsies in hepatocellular carcinoma: are we winning? J Clin Med. 2020;9(5):1541. doi:10.3390/jcm9051541
   PubMed Web of Science ®Google Scholar
• von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69(11):2025–2034. doi:10.1136/gutjnl-2019-320282
   PubMed Web of Science ®Google Scholar
• Ha Y, Kim TH, Shim JE, et al. Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study. Hepatol Int. 2019;13(6):726–735. doi:10.1007/s12072-019-09994-9
   PubMed Web of Science ®Google Scholar
• Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gas Hepatol. 2020;18(13):2879–2902.e2879. doi:10.1016/j.cgh.2020.04.019
   PubMed Web of Science ®Google Scholar
• Lim SB, Yeo T, Lee WD, et al. Addressing cellular heterogeneity in tumor and circulation for refined prognostication. Proc Natl Acad Sci USA. 2019;116(36):17957–17962. doi:10.1073/pnas.1907904116
   PubMed Web of Science ®Google Scholar
• Anvari S, Osei E, Maftoon N. Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci Rep. 2021;11(1):15477. doi:10.1038/s41598-021-94735-y
   PubMed Web of Science ®Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Throm Haemost. 2011;9(2):237–249. doi:10.1111/j.1538-7836.2010.04131.x
   PubMed Web of Science ®Google Scholar
• Bu J, Jeong WJ, Jafari R, et al. Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. Biosens Bioelectron. 2022;213:114445. doi:10.1016/j.bios.2022.114445
   PubMed Web of Science ®Google Scholar
• Lou XL, Sun J, Gong SQ, Yu XF, Gong R, Deng H. Interaction between circulating cancer cells and platelets: clinical implication. Chin J Cancer Res. 2015;27(5):450–460. doi:10.3978/j.issn.1000-9604.2015.04.10
   PubMed Web of Science ®Google Scholar
• Pereira-Veiga T, Schneegans S, Pantel K, Wikman H. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. Cell Rep. 2022;40(9):111298. doi:10.1016/j.celrep.2022.111298
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12(1):133. doi:10.1186/s13045-019-0806-6
   PubMed Web of Science ®Google Scholar
• Tesfamariam B, Wood SC. Targeting glycoprotein VI to disrupt platelet-mediated tumor cell extravasation. Pharmacol Res. 2022;182:106301. doi:10.1016/j.phrs.2022.106301
   PubMed Web of Science ®Google Scholar
• Chai S, Matsumoto N, Storgard R, et al. Platelet-coated circulating tumor cells are a predictive biomarker in patients with metastatic castrate-resistant prostate cancer. Mol Cancer Res. 2021;19(12):2036–2045. doi:10.1158/1541-7786.Mcr-21-0383
   PubMed Web of Science ®Google Scholar
• Abdallah EA, Souza ESV, Braun AC, et al. A higher platelet-to-lymphocyte ratio is prevalent in the presence of circulating tumor microemboli and is a potential prognostic factor for non-metastatic colon cancer. Transl Oncol. 2021;14(1):100932. doi:10.1016/j.tranon.2020.100932
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–699. doi:10.1016/0168-8278(95)80226-6
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503. doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e
   PubMed Web of Science ®Google Scholar
• Bezerra AS, D’Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement? Am J Roentgenol. 2005;184(5):1510–1513. doi:10.2214/ajr.184.5.01841510
   PubMed Web of Science ®Google Scholar
• de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–176. doi:10.1016/j.jhep.2005.05.009
   PubMed Web of Science ®Google Scholar
• Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int. 2020;14(6):1034–1047. doi:10.1007/s12072-020-10111-4
   PubMed Web of Science ®Google Scholar
• Goh BK, Teo JY, Chan CY, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: implications on the current AJCC staging system. J Surg Oncol. 2016;113(1):89–93. doi:10.1002/jso.24099
   PubMed Web of Science ®Google Scholar
• Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma. Cancers. 2020;12:11. doi:10.3390/cancers12113215
   Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Meta Rev. 2017;36(2):249–262. doi:10.1007/s10555-017-9673-1
   PubMed Web of Science ®Google Scholar
• Papa AL, Jiang A, Korin N, et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11:479. doi:10.1126/scitranslmed.aau5898
   Web of Science ®Google Scholar
• Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019;25(4):641–655. doi:10.1038/s41591-019-0379-5
   PubMed Web of Science ®Google Scholar
• Ma C, Fu Q, Diggs LP, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022;40(9):986–998.e985. doi:10.1016/j.ccell.2022.08.004
   PubMed Web of Science ®Google Scholar
• Wang B, Zhu J, Ma X, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chimica Acta. 2019;495:191–197. doi:10.1016/j.cca.2019.03.1634
   PubMed Web of Science ®Google Scholar
• Bihari C, Rastogi A, Shasthry SM, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS. 2016;124(9):776–786. doi:10.1111/apm.12574
   PubMed Web of Science ®Google Scholar
• Wu CJ, Chau GY, Lee IC, et al. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc. 2021;120(8):1563–1571. doi:10.1016/j.jfma.2020.11.019
   PubMed Web of Science ®Google Scholar
• Asesio N, Pollo-Flores P, Caliez O, et al. Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. Digest Liver Dis. 2022;54(5):645–653. doi:10.1016/j.dld.2021.09.004
   Web of Science ®Google Scholar
• Midorikawa Y, Takayama T, Higaki T, et al. High platelet count as a poor prognostic factor for liver cancer patients without cirrhosis. Biosci Trends. 2020;14(5):368–375. doi:10.5582/bst.2020.03230
   PubMed Web of Science ®Google Scholar